Airway mucus hypersecretion and secretion retention can result from inflammation, irritation, stimulation, or mucus-producing tumors. Secretion clearance can be furthered hampered by ciliary dysfunction and by weakness or restrictive lung disease, leading to an ineffective cough. There are a number of different mucoactive medications that have been used to reduce hypersecretion, make secretions easier to transport, or increase the efficiency of cough or mucus clearance. In this paper, I review the pathophysiology of secretory hyper-responsiveness and mucus hypersecretion and discuss the different aerosol medications that can be used to augment secretion clearance.
KaterA, HenkeMO, RubinBK. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. Ann NY Acad Sci, 2007; 1112:140-153.
2.
RubinBK. Mucus, phlegm, and sputum in cystic fibrosis. Respir Care, 2009; 54(6):726-732; discussion 732.
3.
VoynowJA, RubinBK. Mucus, mucins, and sputum. Chest, 2009; 135(2):505-512.
4.
RubinBK. The role of mucus in cough research. Lung, 2010; 188(Suppl 1):S69-S72.
5.
RubinBK. The pharmacologic approach to airway clearance: mucoactive medications. Paediatr Respir Rev, 2006; 7(Suppl 1):S215-S219.
6.
KallstromTJ, AARC. Clinical practice guideline. Bland aerosol administration–2003 revision and update. Respir Care, 2003; 48(5):529-533.
7.
RubinBK. Mucolytics, expectorants, and mucokinetic medications. Respir Care, 2007; 52(7):859-865.
8.
Hoffer-SchaeferA, RozyckiHJ, YoppMA, RubinBK. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with an acute respiratory tract infections. Respir Care, 2014; 59(5):631-636.
9.
ElkinsMR, RobinsonM, RoseBR, HarbourC, MoriartyCP, MarksGB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med, 2006; 354(3):229-240.
10.
SuriR, GrieveR, NormandC, MetcalfeC, ThompsonS, WallisC, BushA. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax, 2002; 57(10):841-846.
11.
DaviskasE, RubinBK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med, 2013; 7(1):65-75.
12.
MossRB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr, 2013; 162(4):676-680.
HenkeMO, RennerA, HuberRM, SeedsMC, RubinBK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol, 2004; 31(1):86-91.
15.
BlackPN, Morgan-DayA, McMillanTE, PoolePJ, YoungRP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulmon Med, 2004; 4:13.
16.
TamJ, NashEF, RatjenF, TullisE, StephensonA. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev, 2013; 7:CD007168.
17.
LaubeBL, AuciRM, ShieldsDE, ChristiansenDH, LucasMK, FuchsHJ, RosensteinBJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med, 1996; 153(2):752-760.
18.
RubinBK. Who will benefit from DNase?. Pediatr Pulmonol, 1999; 27(1):3-4.
19.
O'DonnellAE, BarkerAF, IlowiteJS, FickRB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest, 1998; 113(5):1329-1334.
20.
O'RiordanTG, MaoW, PalmerLB, ChenJJ. Assessing the effects of racemic and single enantiomer albuterol on airway secretions in long-term intubated patients. Chest, 2006; 129(1):124-132.
21.
AnzuetoA, JubranA, OharJA, PiquetteCA, RennardSI, ColiceG, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA, 1997; 278(17):1426-1431.
BatemanED, RennardS, BarnesPJ, DicpinigaitisPV, GosensR, GrossNJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther, 2009; 22(6):533-542.
24.
TamaokiJ, ChiyotaniA, KobayashiK, SakaiN, KanemuraT, TakizawaT. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis, 1992; 145(3):548-552.
25.
MadsenP, ShahSA, RubinBK. Plastic bronchitis: new insights and a classification scheme. Paediatr Respir Rev, 2005; 6(4):292-300.
26.
EasonDE, CoxK, MoskowitzWB. Aerosolised heparin in the treatment of Fontan-related plastic bronchitis. Cardiol Young, 2014; 24(1):140-142.
27.
LaubeBL, LinksJM, LaFranceND, WagnerHNJr, RosensteinBJ. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest, 1989; 95(4):822-830.
28.
RubinBK. Pediatric aerosol therapy: new devices and new drugs. Respir Care, 2011; 56(9):1411-1421; discussion 1421-1423.
29.
RubinBK, WilliamsRW. Emerging aerosol drug delivery strategies: from bench to clinic. Adv Drug Deliv Rev, 2014; 75:141-148.
30.
RubinBK. Air and soul: the science and application of aerosol therapy. Respir Care, 2010; 55(7):911-921.
31.
WilliamsR, RubinBK. Aerosol therapy for the therapy of CF. In: BushA, BiltonD, HodsonM. Hodson and Geddes' cystic fibrosis, 4th edition. London: Taylor & Francis; 2015:279-297.
LaubeBL. Devices for aerosol delivery to treat sinusitis. J Aerosol Med, 2007; 20(Suppl 1):S5-S17; discussion S17-S18.
34.
MainzJG, SchienC, SchillerI, SchädlichK, KoitschevA, KoitschevC, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros, 2014; 13(4):461-470.
35.
FlumePA, RobinsonKA, O'SullivanBP, FinderJD, VenderRL, Willey-CourandDB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care, 2009; 54(4):522-537.
36.
DenticeR, ElkinsM. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev, 2013; 6:CD007923.
37.
MesquitaFO, Galindo-FilhoVC, NetoJL, GalvãoAM, BrandãoSC, FinkJB, Dornelas-de-AndradeA. Scintigraphic assessment of radio-aerosol pulmonary deposition with the Acapella positive expiratory pressure device and various nebulizer configurations. Respir Care, 2014; 59(3):328-333.
38.
BerlinskiA. In vitro evaluation of positive expiratory pressure devices attached to nebulizers. Respir Care, 2014; 59(2):216-222.
39.
SuggettJ, MitchellJ, AvvakoumovaV, AliR, SchneiderH. Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation with oscillating positive expiratory pressure device (OPEP) offers potential for simultaneous therapy. Eur Respir J, 2013; 42(Suppl 57):P2115.
